Instructor in Medicine, Massachusetts General Hospital
Oncology
Dr. Steven L. McAfee, MD
|
|
Give Review
Dr. Steven L. McAfee is an expert in the field of Oncology. He studied medicine at Tufts University School of Medicine. Tufts University School of Medicine is ranked 49 in research and 52 in primary care medicine Steven McAfee is also a published MD. He has 62 publication published. The most recent publication is: Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Steven McAfee is registered with Medicare and accepts Medicare payments.
Publications
- Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL.
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloi...
- Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem Cell transplantation.
- Chromosome 17p deletion in a case of T-cell Acute lymphoblastic lymphoma.
- Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem Cell transpl...
- Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
- Engraftment Syndrome after allogeneic hematopoietic cell transplantation in adults.
- Phase I Study of Urate Oxidase in the Reduction of Acute Graft-vs-Host Disease Following Myeloablative Allogeneic Stem Cell Transplantation.
- Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem Cell transplantation for hematologic malignancies.
- Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML).
- Risk factors for invasive fungal Disease after allogeneic hematopoietic stem cell transplantation: a single center experience.
- Association between baseline body mass index (BMI) and overall survival among patients over age 60 with Acute myeloid leukemia (AML).
- Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia.
- Expression of ñ4ò7 integrin on memory CD8(+) T cells at the presentation of Acute intestinal GVHD.
- Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation.
- Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU, and etoposide (CBV) followed by autologous stem Cell transplant.
- Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation.
- Autologous stem cell transplantation with thiotepa, busulfan and cyclophosphamide (tbc) conditioning in patients with cns involvement by non-hodgkin Lymphoma.
- High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin Lymphoma.
- Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal Disease.
- Donor-derived second hematologic malignancies after cord blood transplantation.
- Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma: a single-institution exp...
- High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
- Nonmyeloablative haploidentical stem-Cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.
- Dose-escalated total body irradiation and autologous stem Cell transplantation for refractory hematologic malignancy.
- Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal Disease: the induction of a...
- Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
- Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.
- Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem Cell transplantation.
- Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplan...
- NK Cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic Cell transplantation following nonmyeloablative conditioning using...
- Regulatory T-Cell recovery in recipients of haploidentical nonmyeloablative hematopoietic Cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without...
- Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with Acute myelogenous leukemia.
- Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor.
- Phase I trial of parathyroid hormone to facilitate stem Cell mobilization.
- Mixed lymphohaemopoietic chimerism and graft-versus-Lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.
- Clinical outcomes of late rather than early full-donor chimerism in patients with advanced Lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT.
- Comparison of outcomes after transplantation of peripheral blood stem Cells versus bone marrow following an identical nonmyeloablative conditioning regimen.
- Early host CD8 T-Cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-Cell responses associated with marrow graft rejection following nonmye...
- Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal Disease.
- Successful pregnancy after high-dose cyclophosphamide, carboplatinum, and taxol with peripheral blood stem Cell transplant in a young woman with ovarian carcinoma.
- Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory Lymphoma receiving nonmyeloablative conditioning and a haploidentical ...
- Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
- Cardiac transplantation followed by dose-intensive melphalan and autologous stem-Cell transplantation for light chain amyloidosis and heart failure.
- Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin''s Lymphoma.
- Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants.
- Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host Disease, and antitumor response in patients with advanced hematologic malignanci...
- Successful allogeneic stem Cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem Cell tran...
- Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem Cell rescue.
- A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis followi...
- Late onset veno-occlusive Disease following high-dose chemotherapy and stem cell transplantation.
- A comparison of related and unrelated marrow donors.
- Methods of stem Cell mobilization.
- High dose chemotherapeutic strategies in the treatment of epithelial ovarian carcinoma.
- Early vs delayed administration of G-CSF following autologous peripheral blood stem Cell transplantation.
- High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem Cell transplantation followed by maintenance IL-2 therapy in metastatic bre...
- High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.
- Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation.
- Between parent and child: negotiating cancer treatment in adolescents.
- Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.
- Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell Lymphoma who failed initial rituximab,...
Schools
Tufts University
University Of Missouri Columbia Campus
Presby University Hospital
Georgetown University Hospital
Mass Genl Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Harvard Pilgrim Health Care PPO
- Medicare Advantage PFFS
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Network Health
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Georgetown University Hospital -
Tufts University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1588647945 | |
| NPPES Provider LastName | MCAFEE | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 021142617 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1314.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 264.0 | |
| Percent Opioid Claims | 20.09 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1588647945 |
| Last Name Of The Provider | MCAFEE |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Francois Mercier, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brijal K. Dave, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy Y. Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane A. Healy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shuchi S. Pandya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. Lathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam J. Bass, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ephraim P. Hochberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas R. Spitzer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy Berliner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beverly Moy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Toni K. Choueiri, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Noopur S. Raje, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Doweiko, MD |
|
|
Dr. Franklin W. Huang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen H. Antman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dongsheng Xu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lija Joseph, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Keith E. Stuart, MD
This Doctor is OpenDoctor Recommended.
|